138 related articles for article (PubMed ID: 6968751)
61. Induction of thromboxane release from macrophages by anaphylatoxic peptide C3a of complement and synthetic hexapeptide C3a 72-77.
Hartung HP; Bitter-Suermann D; Hadding U
J Immunol; 1983 Mar; 130(3):1345-9. PubMed ID: 6600482
[TBL] [Abstract][Full Text] [Related]
62. Identification and synthesis of a receptor binding site of human anaphylatoxin C5a.
Kawai M; Quincy DA; Lane B; Mollison KW; Luly JR; Carter GW
J Med Chem; 1991 Jul; 34(7):2068-71. PubMed ID: 2066977
[TBL] [Abstract][Full Text] [Related]
63. The anaphylatoxic peptide C3a of guinea pig complement. I. Purification, physicochemical and antigenetic properties.
Meuer S; Becker S; Hadding U; Bitter-Suermann D
Z Immunitatsforsch Immunobiol; 1978 Mar; 154(2):135-46. PubMed ID: 77089
[TBL] [Abstract][Full Text] [Related]
64. Designing of an orally active complement C3a agonist peptide with anti-analgesic and anti-amnesic activity.
Jinsmaa Y; Takenaka Y; Yoshikawa M
Peptides; 2001 Jan; 22(1):25-32. PubMed ID: 11179594
[TBL] [Abstract][Full Text] [Related]
65. Chimeric receptors of the human C3a receptor and C5a receptor (CD88).
Crass T; Ames RS; Sarau HM; Tornetta MA; Foley JJ; Köhl J; Klos A; Bautsch W
J Biol Chem; 1999 Mar; 274(13):8367-70. PubMed ID: 10085065
[TBL] [Abstract][Full Text] [Related]
66. Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum.
Bokisch VA; Müller-Eberhard HJ; Cochrane CG
J Exp Med; 1969 May; 129(5):1109-30. PubMed ID: 5778786
[TBL] [Abstract][Full Text] [Related]
67. In vivo effects of C3a on neutrophils and its contribution to inflammatory lung processes in a guinea-pig model.
Hoffmann T; Böttger EC; Baum HP; Messner M; Hadding U; Bitter-Suermann D
Clin Exp Immunol; 1988 Mar; 71(3):486-92. PubMed ID: 3260158
[TBL] [Abstract][Full Text] [Related]
68. Structure-function studies in a series of carboxyl-terminal octapeptide analogues of anaphylatoxin C5a.
Kawai M; Quincy DA; Lane B; Mollison KW; Or YS; Luly JR; Carter GW
J Med Chem; 1992 Jan; 35(2):220-3. PubMed ID: 1732540
[TBL] [Abstract][Full Text] [Related]
69. Cardiac anaphylaxis. Complement activation as an amplification system.
del Balzo U; Polley MJ; Levi R
Circ Res; 1989 Sep; 65(3):847-57. PubMed ID: 2475275
[TBL] [Abstract][Full Text] [Related]
70. Design, structure-activity, and molecular modeling studies of potent renin inhibitory peptides having N-terminal Nin-For-Trp (Ftr): angiotensinogen congeners modified by P1-P1' Phe-Phe, Sta, Leu psi[CH(OH)CH2]Val or leu psi[CH2NH]Val substitutions.
Sawyer TK; Pals DT; Mao B; Staples DJ; de Vaux AE; Maggiora LL; Affholter JA; Kati W; Duchamp D; Hester JB
J Med Chem; 1988 Jan; 31(1):18-30. PubMed ID: 3275777
[TBL] [Abstract][Full Text] [Related]
71. Proton nuclear magnetic resonance study of the third component of complement: solution conformation of the carboxyl-terminal segment of C3a fragment.
Muto Y; Fukumoto Y; Arata Y
Biochemistry; 1985 Nov; 24(23):6659-65. PubMed ID: 3878728
[TBL] [Abstract][Full Text] [Related]
72. Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells.
el-Lati SG; Dahinden CA; Church MK
J Invest Dermatol; 1994 May; 102(5):803-6. PubMed ID: 7513741
[TBL] [Abstract][Full Text] [Related]
73. Action of thrombin receptor polypeptide in gastric smooth muscle: identification of a core pentapeptide retaining full thrombin-mimetic intrinsic activity.
Hollenberg MD; Yang SG; Laniyonu AA; Moore GJ; Saifeddine M
Mol Pharmacol; 1992 Aug; 42(2):186-91. PubMed ID: 1325029
[TBL] [Abstract][Full Text] [Related]
74. Active recombinant C3a of human anaphylatoxin produced in Escherichia coli.
Fukuoka Y; Yasui A; Tachibana T
Biochem Biophys Res Commun; 1991 Mar; 175(3):1131-8. PubMed ID: 2025244
[TBL] [Abstract][Full Text] [Related]
75. Complement activation and anaphylatoxin (C3a and C5a) formation in preeclampsia and by amniotic fluid.
Haeger M; Bengtson A; Karlsson K; Heideman M
Obstet Gynecol; 1989 Apr; 73(4):551-6. PubMed ID: 2784554
[TBL] [Abstract][Full Text] [Related]
76. Angiography and complement activation. Evidence for generation of C3a anaphylatoxin by intravascular contrast agents.
Westaby S; Dawson P; Turner MW; Pridie RB
Cardiovasc Res; 1985 Feb; 19(2):85-8. PubMed ID: 3872180
[TBL] [Abstract][Full Text] [Related]
77. Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase.
Schwartz LB; Kawahara MS; Hugli TE; Vik D; Fearon DT; Austen KF
J Immunol; 1983 Apr; 130(4):1891-5. PubMed ID: 6339618
[TBL] [Abstract][Full Text] [Related]
78. NH2-terminal pentapeptide of endothelial interleukin 8 is responsible for the induction of apoptosis in leukemic cells and has an antitumor effect in vivo.
Terui Y; Tomizuka H; Mishima Y; Ikeda M; Kasahara T; Uwai M; Mori M; Itoh T; Tanaka M; Yamada M; Shimamura S; Ishizaka Y; Ozawa K; Hatake K
Cancer Res; 1999 Nov; 59(22):5651-5. PubMed ID: 10582677
[TBL] [Abstract][Full Text] [Related]
79. Chemotactic effects of the complement-derived peptides C3a, C3ai and C5a (classical anaphylatoxin) on rabbit and guinea-pig polymorphonuclear leukocytes.
Damerau B; Grünefeld E; Vogt W
Naunyn Schmiedebergs Arch Pharmacol; 1978 Nov; 305(2):181-4. PubMed ID: 732894
[TBL] [Abstract][Full Text] [Related]
80. Role of histamine in the spasmogenic effect of the complement peptides C3a and C5a-desArg (classical anaphylatoxin).
Sorgenfrei J; Damerau B; Vogt W
Agents Actions; 1982 Apr; 12(1-2):118-21. PubMed ID: 6177210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
